MX2020011453A - Combinaciones para tratar el cancer. - Google Patents
Combinaciones para tratar el cancer.Info
- Publication number
- MX2020011453A MX2020011453A MX2020011453A MX2020011453A MX2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A MX 2020011453 A MX2020011453 A MX 2020011453A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- treating cancer
- combinations
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se desvelan métodos de tratamiento del cáncer que comprenden administrar ácido 17-cloro-5,13,14,22-tetrametil-28-oxa-2,9-ditia- 5,6,12,13,22-pentaazaheptaciclo[27.7.1.14,7.011,15.016,21.020,24. 030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35- tridecaeno-23-carboxílico, una sal farmacéuticamente aceptable del mismo; y acalabrutinib, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862664356P | 2018-04-30 | 2018-04-30 | |
PCT/IB2019/053491 WO2019211721A1 (en) | 2018-04-30 | 2019-04-29 | Combinations for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011453A true MX2020011453A (es) | 2020-12-07 |
Family
ID=66794041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011453A MX2020011453A (es) | 2018-04-30 | 2019-04-29 | Combinaciones para tratar el cancer. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210030718A1 (es) |
EP (1) | EP3787620A1 (es) |
JP (1) | JP2021522246A (es) |
KR (1) | KR20210005182A (es) |
CN (1) | CN112040944A (es) |
AU (1) | AU2019263026B2 (es) |
BR (1) | BR112020022020A2 (es) |
CA (1) | CA3097486A1 (es) |
EA (1) | EA202092540A1 (es) |
MA (1) | MA52499A (es) |
MX (1) | MX2020011453A (es) |
SG (1) | SG11202010528XA (es) |
TW (1) | TW202014184A (es) |
WO (1) | WO2019211721A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023501317A (ja) * | 2019-11-04 | 2023-01-18 | アストラゼネカ・アクチエボラーグ | B細胞悪性腫瘍を処置するためのアカラブルチニブとカピバセルチブとの治療的組み合わせ |
MX2022007474A (es) * | 2019-12-18 | 2022-08-04 | Zeno Man Inc | Compuestos macrociclicos. |
CN117651554A (zh) | 2021-06-11 | 2024-03-05 | 吉利德科学公司 | Mcl-1抑制剂与抗癌剂的组合 |
US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2841886C (en) | 2011-07-19 | 2016-08-16 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
CN106714909A (zh) * | 2014-08-08 | 2017-05-24 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶抑制剂组合及其用途 |
AR108301A1 (es) * | 2016-04-22 | 2018-08-08 | Astrazeneca Ab | Inhibidores de mcl-1 y métodos de uso de los mismos |
CN107056786B (zh) * | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | 阿卡替尼的制备方法 |
-
2019
- 2019-03-05 TW TW108107170A patent/TW202014184A/zh unknown
- 2019-04-29 WO PCT/IB2019/053491 patent/WO2019211721A1/en unknown
- 2019-04-29 SG SG11202010528XA patent/SG11202010528XA/en unknown
- 2019-04-29 AU AU2019263026A patent/AU2019263026B2/en not_active Ceased
- 2019-04-29 MA MA052499A patent/MA52499A/fr unknown
- 2019-04-29 KR KR1020207034122A patent/KR20210005182A/ko unknown
- 2019-04-29 US US17/047,931 patent/US20210030718A1/en not_active Abandoned
- 2019-04-29 CA CA3097486A patent/CA3097486A1/en active Pending
- 2019-04-29 CN CN201980028857.5A patent/CN112040944A/zh active Pending
- 2019-04-29 EP EP19729355.8A patent/EP3787620A1/en not_active Withdrawn
- 2019-04-29 BR BR112020022020-5A patent/BR112020022020A2/pt not_active IP Right Cessation
- 2019-04-29 EA EA202092540A patent/EA202092540A1/ru unknown
- 2019-04-29 MX MX2020011453A patent/MX2020011453A/es unknown
- 2019-04-29 JP JP2020559437A patent/JP2021522246A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2019263026A1 (en) | 2020-12-17 |
AU2019263026B2 (en) | 2022-06-30 |
EA202092540A1 (ru) | 2021-03-17 |
EP3787620A1 (en) | 2021-03-10 |
BR112020022020A2 (pt) | 2021-02-02 |
CN112040944A (zh) | 2020-12-04 |
KR20210005182A (ko) | 2021-01-13 |
SG11202010528XA (en) | 2020-11-27 |
TW202014184A (zh) | 2020-04-16 |
WO2019211721A1 (en) | 2019-11-07 |
JP2021522246A (ja) | 2021-08-30 |
MA52499A (fr) | 2021-04-14 |
CA3097486A1 (en) | 2019-11-07 |
US20210030718A1 (en) | 2021-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011453A (es) | Combinaciones para tratar el cancer. | |
MX2019013954A (es) | Inhibidores covalentes de kras. | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
MX2018000777A (es) | Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c. | |
PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
MX2020010369A (es) | Particulas implantables y metodos relacionados. | |
MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
MX2018004309A (es) | Terapias combinadas para tratar el cancer. | |
WO2016133903A3 (en) | Combination therapy for cancer treatment | |
MX2021009439A (es) | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. | |
CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
EP4364741A3 (en) | Polymorphic form of tg02 | |
MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
MX2020010618A (es) | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2021007247A (es) | Derivados de rapamicina. | |
PH12020552274A1 (en) | Formulations of an axl/mer inhibitor | |
JOP20220042A1 (ar) | طرق لعلاج فرط فينيل ألانين الدم | |
MX2021012105A (es) | Compuestos de pirrol. | |
MX2022005358A (es) | Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso. | |
MX2021014523A (es) | Metodos para tratar colangiocarcinoma. |